

## Unexplained Male Infertility – Looking Beyond Routine Semen Analysis

Alaa Hamada,<sup>1</sup> Sandro Esteves<sup>2</sup> and Ashok Agarwal<sup>3</sup>

1. Fellow in Andrology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio, US;

2. Director, Androfert, Campinas, Sao Paulo, Brazil; 3. Professor, Lerner College of Medicine, Director, Andrology Laboratory and Director, Center for Reproductive Medicine, Cleveland Clinic, Cleveland, Ohio, US

### Abstract

Unexplained infertility is a diagnosis reserved for couples in whom routine semen analysis is within normal values and female infertility factors have been ruled out. Its reported prevalence ranges from 6–27 % depending on how exhaustive the patient work-up is. Despite differing according to urological societies, recommendation for male infertility evaluation usually considers routine semen analysis results as surrogates for fertility potential. Male infertility evaluation, however, must go far beyond counting spermatozoa and assessing motility and morphology. It has to be complemented with comprehensive history taking, proper clinical examination and relevant endocrine, genetic and/or other investigations. There is a broad spectrum of potential aetiologies of unexplained male infertility (UMI), ranging from the simple couple's miscomprehension of the concept of the female fertile window to complex molecular and functional defects involving either the male or the female, or both. Novel contemporary technologies added to the current knowledge on this subject highlight a case for careful reconsideration before clinicians make treatment decisions for patients with unexplained infertility.

### Keywords

Infertility, male, female, diagnosis, treatment, semen analysis, oxidative stress, DNA damage, genetics, assisted reproductive techniques, andrology

**Disclosure:** The authors have no conflicts of interest to declare.

**Received:** 28 February 2012 **Accepted:** 26 March 2012 **Citation:** *European Urological Review*, 2012;7(1):90–6

**Correspondence:** Ashok Agarwal, Cleveland Clinic, Desk A19.1, 9500 Euclid Avenue, Cleveland, Ohio 44195, US. E: agarwaa@ccf.org

Infertility is customarily defined as the inability of a sexually active, non-contracepting couple to achieve spontaneous pregnancy in one year.<sup>1</sup> It has been estimated that 15 % of couples seek medical assistance for infertility and the origins of the problem seem to be equally shared between male and female partners.<sup>1</sup> Unfortunately, the cause of fertility impairment cannot be determined in nearly half of the cases despite the availability of a relatively broad range of diagnostic tests and eventually 5 % of couples remain unwillingly childless.<sup>1–3</sup>

Infertility of unknown origin comprises both idiopathic male infertility and unexplained infertility. Men presenting with idiopathic infertility (30–40 %)<sup>1,2</sup> have reduced semen quality with no obvious abnormalities in their history of fertility problems and both physical examination and endocrine laboratory testing. The category 'unexplained infertility' is reserved for couples in whom routine semen analysis is within normal values and female infertility factors have been ruled out.<sup>4</sup> Its highly variable reported prevalence ranging from 6–27 %<sup>1–6</sup> strongly depends on how exhaustive is the couple evaluation. In countries with limited resources for diagnosis it is likely that the prevalence of unexplained infertility increases.<sup>7</sup>

Recommendations for male infertility evaluation based on semen analyses results may be confounded due to the limited validity of routine semen analysis as surrogates for the assessment of male fertility potential.<sup>7,8</sup> The prognostic fertility value of semen characteristics, such as sperm concentration, percent motility and morphology, is influenced by sexual activity, function of the accessory sex glands and other conditions. Nonetheless, routine semen analysis does not account for

sperm dysfunctions such as immature chromatin or DNA damage. In addition, the assumption that one ejaculate is representative of a given man's semen profile argues against the current knowledge of the high biological variability of semen variables from the same individuals. Lastly, criteria for semen normality vary according to the World Health Organization (WHO) laboratory manual edition for the examination and processing of human semen edition.<sup>9–11</sup> As noted, in its newly released edition the WHO has established new reference values for human semen characteristics which are markedly lower than those previously reported.<sup>8,10</sup> The utilisation of the new WHO manual reference values into clinical practice will likely result in a re-classification of many of the infertile couples. Specifically, those couples previously classified as having male factor infertility with sperm parameters above the new reference limits but below the previous values (WHO, 1999) will now be diagnosed as having unexplained infertility.

These introductory considerations highlight the current importance of unexplained infertility and the shortcomings of routine semen analysis. The male evaluation regarding fertility must go far beyond counting spermatozoa and assessing motility and morphology. It has to be complemented with a proper clinical examination comprehensive history taking and relevant endocrine, genetic and/or other investigations.

### Candidate Aetiologies of Unexplained Male Infertility

The following possibilities should be considered in the assessment of men with unexplained infertility:

- presence of a female factor;
- inappropriate coital habits;
- erectile dysfunction;
- presence of antisperm antibodies (autoimmune infertility); and
- sperm dysfunctions.<sup>12</sup>

The first three conditions can be ruled out by comprehensive history taking and through gynaecological evaluation whereas modern andrology aids in the evaluation of the last two possibilities.

### Autoimmune Male Infertility

It is defined as an improper bodily immune response, whether humoral or cellular, against sperm antigens causing sperm functional dysfunction and rendering the male infertile. Antisperm antibodies (ASA), the hallmark of autoimmune infertility, are implicated in sperm dysfunction by their direct effect on various sperm antigens. ASA may interfere with various sperm functions such as inducing acrosome reaction prematurity and activating apoptosis. ASA may also hinder fertilisation event by inhibition of cervical mucus penetration, zona pellucida (ZP) binding or sperm-oocyte fusion. Furthermore, ASA may change some macromolecular and sub-cellular function by altering chaperone function, protein folding and disulphide bonds.<sup>13</sup> These alterations ultimately result in a decrease in pregnancy rates.<sup>14</sup>

About 10 % of infertile men have ASA compared to only 2 % in fertile counterparts.<sup>15</sup> Nevertheless, elevated levels of ASA may be found in as high as 40 % of men with unexplained male infertility (UMI).<sup>16</sup> The disruption of blood-testis barriers by immunosuppression defects or genital tract insults are the primary mechanisms responsible for leakage of sperm antigens and formation of ASA. ASA can be found in the serum, seminal plasma and sperm-bound. However, it is still unknown whether ASA are locally formed within the genital tract or merely transuded from the serum. The pathogenesis of autoimmune male infertility is further complicated by the observation that 7–17 % of infertile women also produce antisperm antibodies in their cervical fluids.<sup>17,18</sup>

Elevated ASA titers can be found in men with normal conventional semen parameters.<sup>19</sup> Nonetheless, attention should be paid to sperm agglutination, which is the only finding highly suggestive of elevated ASA titers.<sup>14</sup> However, sperm agglutination is time-dependent and rarely involves a large proportion of motile spermatozoa immediately after liquefaction, even when all ejaculated spermatozoa are antibody coated.<sup>14</sup> Along the same lines, both the immobilising and the apoptogenic impacts of ASA on spermatozoa require complement activation which is prevented by potent anticomplement substances in the seminal plasma such as membrane cofactor protein (MCP) or decay accelerating factor (DAF).<sup>20,21</sup> Currently, the most popular tests to identify sperm-bound ASA are both the direct immunobead test (IBT) and the direct mixed agglutination reaction (MAR).<sup>22</sup>

The diagnosis of immunological infertility requires two conditions to be satisfied:<sup>23</sup>

- a minimum of 50 % percent of motile spermatozoa (progressive and non-progressive) have beads attached to their surface. It should be noted, however, that particle binding restricted to the tail tip is not associated with impaired fertility and can be present in fertile men;<sup>10</sup> and
- sperm-bound antibodies interfere with sperm function; this is usually demonstrated by using functional tests such as the

sperm–mucus penetration test, zona binding assays and the acrosome reaction.

### Genetic Causes of Unexplained Male Infertility

Genetic abnormalities causing male infertility include alterations in sperm chromosomal complement, sperm DNA integrity defects and gene mutation and polymorphisms.

### Alterations in Sperm Chromosomal Complement

Non-disjunction events during gametogenesis result in either extra or missing chromosome that lead to aberrations in numerical chromosomal complement; such aberration is termed 'aneuploidy'. On the other hand, structural chromosomal complement defects such as deletions, translocations and inversions may also occur in spermatozoa or oocytes due to chromosomal insults. Both structural and numerical chromosomal complement defects can give rise to dysfunctional sperm thus impacting on male fertility and pregnancy viability.<sup>24</sup>

Although sperm chromosomal aneuploidy rates are inversely correlated to sperm concentration and total progressive motility,<sup>25,26</sup> spermatozoa of normozoospermic infertile males may also harbour such defects.<sup>27–30</sup> The overall frequency of chromosomally abnormal spermatozoa in the general population is estimated to be 7 %. The mean frequency of disomic sperm (presence of two copies of a chromosome) for autosomes and sex chromosomes are 0.13 and 0.37 %, respectively, while the rate for diploid sperm (two copies of each chromosome) is 0.2 %.<sup>31,32</sup> For normozoospermic infertile males, the corresponding figures are 0.11, 0.44 and 0.3–1.0 %, respectively, but are higher in those with abnormal semen analysis results.<sup>31,32</sup> The exact causes of aneuploidy are mostly unknown, but smoking, alcohol, chemotherapy and ageing may play a role.<sup>33–35</sup>

Interestingly, a variable disomy rate has been observed with sex chromosomes and chromosomes 21 and 22; the higher rate of abnormalities related to chromosomes may be due to their lower rate of meiotic recombination which renders them more prone to non-disjunction.<sup>36</sup> Nonetheless, both morphologically normal and abnormal spermatozoa can be disomic or diploid,<sup>37</sup> or contain damaged DNA.<sup>38</sup> As such, selecting morphologically-normal spermatozoa for assisted reproductive techniques (ART) does not guarantee the absence of chromosomal abnormalities with a possible exception of spermatozoa retaining excess cytoplasm (ERC). In the latter, a greater extent of aneuploidy and diploidy has been observed regardless of the technique used for sperm processing.<sup>39–41</sup>

Similarly as chromosomal aneuploidy, structural chromosomal aberrations such as inversions, deletions, balanced or unbalanced translocations as well as Y-chromosome microdeletions are also associated with abnormal semen parameters. Moreover, such abnormalities are associated with higher miscarriage rates and presumably with higher risk genetic abnormalities in the offspring.<sup>42</sup> Surprisingly, in Y-chromosome microdeletions related infertility, the azoospermia factor c (AZFc) region is prone to many smaller subdeletions than those thought to be caused by intrachromosomal recombination.<sup>43</sup> These partial deletions produce a wide array of phenotypes, ranging from normozoospermia to azoospermia, due to factors that include the interaction of the environment and the genetic background.<sup>33</sup> Chromosomal abnormalities may be detected by using one of the following methods: sperm karyotyping, fluorescence *in situ* hybridisation analysis and quantitative polymerase chain reaction (Q-PCR).

## Sperm DNA Integrity Defects

During spermiogenesis, the haploid sperm chromatin undergoes significant changes in which most histones are replaced first by transition proteins, then by positively charged protamines.<sup>34</sup> By this remodelling process the sperm DNA condenses so tightly that it is resistant to mechanical stresses.<sup>35</sup> When there is a defect in this process or when there is single or double stranded sperm DNA breakage, the sperm DNA integrity is jeopardised and the fertilising capacity of the sperm is undermined.

Sperm DNA integrity is increasingly being distinguished as an important marker of fertilising efficiency and it is associated with better diagnostic and prognostic values than standard sperm parameters. Sperm with DNA damage are more often seen in subfertile/infertile men than in fertile ones.<sup>27-29</sup> Increase of spermatozoa with abnormal chromatin structure or DNA damage (expressed as DNA fragmentation index [DFI]) has been negatively correlated with intracytoplasmic sperm injection (ICSI) and *in vitro* fertilisation (IVF) outcomes.<sup>30</sup> It is known that about 5–8 % of men misdiagnosed as having UMF, according to the normal semen parameters on routine analyses, present sperm DNA integrity defects.<sup>44,45</sup> The aetiologies of such defects are due to variety of extrinsic and intrinsic factors. Heat, smoking, alcohol, radiation and other gonadotoxins are examples of extrinsic factors while protamine deficiency, mutations affecting DNA packaging, reactive oxygen species and ageing are the primary intrinsic factors.<sup>46</sup>

Sperm DNA damage is often assessed by the determination of chromatin compaction or DNA fragmentation, however, each measurement method has certain cut-off value. The former methods examine the accessibility of dyes (acridine blue, aniline blue and chromomycin A3) to nucleoproteins or chromatin after challenging spermatozoa with physical insults; as such, it reflects how susceptible the DNA is, or has been, to noxious agents.<sup>39</sup> On the other hand, DNA fragmentation is measured by detecting single or double strand DNA breaks. Transferase-mediated dTUP nick-end labelling (TUNEL), comet assay, acridine orange test, sperm chromatin structure assay (SCSA) and sperm dispersion test (SCD)<sup>40</sup> are clinically available methods to detect DNA fragmentation. Although they differ in costs and methods, most of the mentioned tests are clinically significant and correlates with sperm function and fertility.<sup>41</sup> For TUNEL, our group at Cleveland Clinic has reported a cut-off DFI of 19.25 % with 100 % specificity to differentiate infertile men with DNA damage from healthy men.<sup>47</sup> Evenson et al. reported 30 % as the threshold for DFI with SCSA.<sup>48</sup>

## Specific Gene Defect – Mutations and Polymorphisms

It is likely that specific genes play a role in patients with UMF since they control meiosis events, spermiogenesis, remodelling, motility, capacitation and fertilisation. In a comparative analytic study on spermatozoa from normozoospermic infertile men and fertile healthy controls using microarray technology, hundreds of gene sequences (targets) were differentially expressed between these two groups; there are few genes that are over-expressed whereas all others are under-expressed in infertile men.<sup>49</sup>

## Oxidative Stress

The imbalance between the production of reactive oxygen species (ROS) and the natural antioxidant defense system is termed as oxidative stress (OS). ROS are specifically defined as a group of oxygen derived metabolites formed by reduction of oxygen such

as superoxide anion, the hydroxyl radical and hydrogen peroxide. Normally, mammalian spermatozoa are redox cells that are able to produce reactive oxygen species and to export them to the extracellular medium to regulate several biological functions such as acrosome reaction, hyperactivation and fertilisation.<sup>50-54</sup>

However, overabundance of these unstable metabolites is harmful to the sperm, causing damage to sperm DNA in the nucleus and mitochondria, and inducing lipid peroxidation in the sperm plasma membrane as well as denaturing cellular protein.<sup>55</sup> In fact, sperm are extremely susceptible to the effect OS because of their high content of polyunsaturated fatty acids (PUFA) in plasma membranes as well as their limited antioxidant defence.<sup>56</sup>

ROS are usually associated with poor semen quality and male infertility. It has been shown that 40–88 % of non-selected infertile patients have high levels of seminal ROS.<sup>57</sup> However, recent reports found that normozoospermic infertile men have higher ROS levels and reduced total antioxidant capacity (TAC) levels than the normozoospermic fertile counterpart.<sup>58</sup> The exact prevalence of OS in normospermic infertile men is unknown. Nevertheless, a controlled study on a limited number of patients detected that 11 % of normospermic men have OS.<sup>58</sup>

The most often used methods for detecting oxidative stress include methods to measure ROS and methods to measure total antioxidant capacity (TAC). In an andrology setting, ROS measurement techniques are divided into two major categories, i.e., direct methods such as chemiluminescence and flow cytometry, and indirect methods, such as the colorimetric one, which target the final products of sperm cell membrane lipid peroxidation. For total antioxidant capacity measurements, several methods are available, such as the ones using enhanced chemiluminescence, spectrophotometry, fluorometry (e.g. ORAC assay) and electrochemistry (coulometry, voltammetry or electron spin resonance assay). Some of them are commercially available, particularly spectrophotometric and fluorometric methods.<sup>59</sup>

## Sperm Fertilisation Defects

Sperm ability to fertilise the ova is associated to their potential of undergoing capacitation, which includes the acquisition of hyperactivated motility, releasing acrosomal enzymes (acrosome reaction) to penetrate the zona pellucida and fusing with the oolema. The competent sperm can successfully achieve all these physiological processes culminating in fruitful fertilization outcome. It has been assumed that normozoospermic infertile men may have defective functional (incompetent) sperm that are unable to fertilise. This assumption is strengthened by the observation of low success rates of IVF and intrauterine insemination (IUI) in certain cases of unexplained infertility.<sup>60</sup>

Sperm fertilising performance can be examined from different angles encompassing all the stages of sperm-egg interactions.

## Zona Pellucida Binding Defects

Sperm binding to ZP3 (the proteinaceous layer that covers the oocyte) induces signal transduction pathways within the spermatozoon, involving multiple proteins, particularly protein-kinases A and C, that lead to the acrosome reaction.<sup>61</sup> Defective ZP bound sperm are present in approximately 15 and 25 % of subfertile men with a normal semen analysis and with abnormal ones, respectively.<sup>62-64</sup>

Such individuals have a reduced chance of achieving successful fertilisation when undergoing IVF.<sup>64</sup> Two tests of sperm binding to the human zona have been described:

- the hemizona assay; and
- the sperm-zona binding ratio test.

### Hyperactivation Defects

Capacitation is a phenomenon involving several physiological and molecular changes that prepare the sperm for fertilisation.<sup>65</sup> Hyperactivation (HA), considered the first step of the complex capacitation process, is characterised by typical swimming pattern of movement shown by most sperm retrieved from the oviductal ampulla at the time of fertilisation.<sup>66</sup> Such motility is essential for the sperm to detach from the oviduct wall, to penetrate into the cumulus oophorus and finally to efficiently drill zona pellucida and reach the oolema.<sup>67</sup>

Assessment of hyperactivation motility *in vitro* involves the use of computerised semen analyser (CASA) in conjunction with the kinematics module to distinguish different subpopulations of motile spermatozoa and to measure the spontaneous hyperactivated sperm and the induced hyperactivation HAmx (using pentoxifylline and progesterone). Hyperactivated spermatozoa can be distinguished from non-hyperactivated ones by their high curvilinear velocity (VCL), low linearity (calculated as straight-line velocity/VCL), and large amplitude of the lateral head displacement. The clinical significance of such data is reflected by their correlation with IVF outcomes and spontaneous pregnancy rates.<sup>68</sup> Mortimer et al. showed that HAmx >50 % is correlated with good *in vitro* fertilisation outcomes.<sup>69</sup>

Recently, it has been suggested that increased intracellular calcium entry through voltage gated calcium channels (CatSper<sup>1-3,5</sup>; Cation channel of Sperm) in the principal piece of the sperm flagellum is the prime mechanism for hyperactivation.<sup>70-72</sup> Defects in the gene coding for this protein is responsible for lack of hyperactivation, as shown in males with mutated CatSper1 gene who are infertile due to poor HA response despite having normal sperm count, morphology and even their initial motility.<sup>73</sup> Further investigation is needed to disclose the minor mutations in human CatSper genes in males with unexplained infertility.

### Acrosome Reaction Defects

The acrosome reaction (AR) is defined as the process of fusion of sperm plasma membrane with outer acrosomal membrane leading to release of exocytotic proteolytic enzymes (acrosine and hyaluronidase) in response to sperm–zona pellucida binding. Human sperm initiate primary binding to the ZP with intact acrosome.<sup>74</sup>

Some patients with unexplained infertility that have normal sperm–ZP binding have defective ZP-induced AR (AR insufficiency), which will result in reduced sperm–ZP penetration and failure of fertilisation.<sup>75</sup> Patients with this condition usually have a long duration of unexplained infertility, normal semen analysis and normal sperm–ZP binding, but show failure of ZP sperm penetration and have zero or low rates of fertilisation with standard *in vitro* fertilization (IVF).<sup>75</sup>

The diagnostic feature is that very low proportions of sperm undergo AR after binding to the ZP.<sup>76</sup> However, those patients achieve high fertilisation and pregnancy rates with intracytoplasmic sperm injection (ICSI).<sup>76</sup> Despite being higher in subfertile men with idiopathic oligozoospermia (65 %) and severe teratozoospermia (62 %, strict

normal sperm morphology  $\leq 5$  %), defective ZP-induced AR (ZPIAR) is found in 25 % of normozoospermic subfertile men.<sup>63</sup>

To assess the inducibility of AR, artificial stimuli are used *in vitro* to challenge the acrosome reaction such as calcium ionophore A23187 and progesterone. Under normal conditions, >15 % AR in response to ionophore treatment is expected.<sup>77</sup> Visualisation of acrosome reacted sperm can be achieved using different techniques as follows:

- birefringence characteristics of acrosomally-reacted spermatozoa under polarised light microscopy;<sup>78</sup>
- fluorescence microscopy after staining with fluoresceinated lectins;<sup>79,80</sup> and
- flow cytometry after addition of fluoresceinated-anti-CD-46 monoclonal antibody.<sup>81</sup>

### Fusogenic Ability Defects

The fusogenic potential of the already capacitated and acrosome-reacted human sperm is represented by their ability to fuse with the vitelline membrane of the oocyte. The fusogenic ability is usually tested by using the sperm penetration assay (SPA), also known as the zona-free hamster oocyte penetration test. It has been reported that 34.1 % of patients with unexplained infertility had <10 % oocyte penetration against 0 % in a control group of fertile men.<sup>82</sup> Various studies have evaluated the ability of the SPA to predict success or failure of IVF. Some investigators have shown no correlation with an abnormal test,<sup>83</sup> whereas others have claimed 100 % predictability.<sup>84</sup> Taking an average from different studies, a normal SPA may have 70 % predictability of normal fertilisation *in vitro*.<sup>85</sup> Semen samples which fail to fertilise hamster ova are usually unable to fertilise human ova.<sup>42</sup> Although the SPA is considered a research tool, it may be of clinical value for men with unexplained infertility with poor fertilisation rate on IVF.

### Work-Up Plan For The Management of Males with Unexplained Infertility

The initial test for couples with UMF is the post-coital test (PCT). PCT is a technically challenging test that must be appropriately timed and performed. Cervical mucus is normally hostile to sperm, except near the time of ovulation. In the peri-ovulatory period, the absence of sperm on a post-coital test in the presence of normal semen parameters suggests incorrect coital technique or failure to ejaculate into the vagina, while the presence of normal sperm numbers exhibiting reduced motility or shaking motility is suggestive of antisperm antibodies.<sup>86</sup> The finding of a normal post-coital test raises the possibility of a functional sperm defect. Assessment of sperm function can be divided into two steps. The first should be directed to check sperm competence before fertilisation by measuring the levels of ROS as well as DNA and chromatin integrity and the second step should include the assessment of sperm fertilisation potential especially for those patients with history of prior failure of conventional IVF. These tests include: sperm-ZP binding assay, capacitation, hyperactivation motility, inducibility of acrosome reaction and the ability of sperm to fuse with the vitelline membrane (zona-free hamster egg penetration test) may be used (see *Table 1*). *Figure 1* depicts an algorithm for the management of unexplained male infertility.

### Treatment


Standardised protocols for treating couples with unexplained infertility are still lacking, not only because the reasons for infertility remains

**Table 1: Diagnostic Testing for Unexplained Male Infertility**

Condition	Target	Testing
Autoimmune infertility	Antispermantibodies	Immunobead test (IBT) and mixed agglutination reaction (MAR)
Genetic causes		
<i>Sperm chromosome complement</i>	Numerical structural autosomal and sex chromosomes	Karyotype, FISH, Yq microdeletion PCR screening
<i>Sperm DNA integrity defects</i>	Sperm chromatin	Chromatin compaction or DNA fragmentation tests
<i>Specific Gene Defects</i>	DNA sequencing	DNA microarray analysis
Oxidative stress	Reactive oxygen species	Direct methods (chemiluminescence and flow cytometry)
	Total antioxidant capacity (TAC)	Direct method (e.g. enhanced chemiluminescence assay)
	Lipid peroxidation	Indirect assays (e.g. colorimetric)
Sperm fertilisation defects	Zona-pellucida binding	Hemizone assay and sperm-zona binding ratio test
	Acrosome reaction	Acrosome reaction challenge test
	Fusogenic ability	Sperm penetration assay

FISH = fluorescence in situ hybridisation; PCR = polymerase chain reaction.

**Figure 1: Proposed Work-up Plan for Unexplained Male Infertility**



ART = assisted reproductive techniques; ICSI = intracytoplasmic sperm injection; ROS = reactive oxygen species.

unrecognisable in several cases but also for the lacking of randomised clinical trials comparing different treatment modalities. However, two lines of treatment are often used based on the infertility duration and age of the female partner.

### Counselling and Watchful Waiting

Counselling is an important aspect in the management of couples with unexplained infertility, particularly with regard to orientation about the physiology of ovulation and the need to time intercourse with the peri-ovulatory period. A detailed medical history may help to disclose any hidden problems such as sexual dysfunction and inadequate coitus habits.

Watchful waiting is advised for young couples with short duration of infertility and presenting with unrecognisable infertility cause after thorough evaluation. Pregnancy may occur spontaneously without any interventions in cases of unexplained infertility.<sup>87</sup> Hull et al. found a cumulative pregnancy rate (PR) ranging from 50–80 % over a three-year period as a function of female age and 30–80 % PR as a function of infertility duration.<sup>88</sup> Cumulative pregnancy rates of 60 % may be achieved within two years.<sup>87</sup> However, infertility periods longer than three years are associated with very low PR of 1–3 % particularly if the female partner is aged 35 years or older.<sup>87</sup> For couples whose time to conceive is longer than three years, the cumulative PR decreases by 2 % for each year of age after 25.7 years.<sup>89</sup> Due to the costs of infertility treatments and given high proportion of couples with unexplained infertility who spontaneously conceive within a two-year period, it is advisable to defer treatment of couples in this time period unless the female partner is aged 35 years or older.

### Intervention

Interventions, which include medication and/or surgery or assisted conception, are justified when specific causes have been identified, or in unexplained infertility of long duration and/or advanced maternal and paternal age.

### Autoimmune Infertility

The best treatment strategy for immunological male infertility has been the microinjection of the compromised spermatozoa into the oocyte cytoplasm (ICSI), thus bypassing sperm-oocyte membrane interaction. Interestingly, the outcome of ICSI in men with autoimmune infertility is not influenced by the percentage of ASA-bound spermatozoa, by the dominant type of antibodies present, or by the location of ASA on the spermatozoa.<sup>90,91</sup>

### Excessive Oxidative Stress

Therapeutic strategies for men with unexplained infertility and elevated levels of oxidative stress markers include lifestyle habits

modification, use of antioxidants and ART. Patients are advised to quit smoking, eat antioxidant-rich food and avoid pollutant environmental conditions. Oral antioxidant therapy such as carnitine, vitamin C, vitamin E, coenzyme Q10, selenium, glutathione, N-acetyl cysteine, carotenoids therapy has attracted attention in the recent years. A recent Cochrane review on the use of antioxidants for male subfertility suggests that antioxidant supplementation may improve the outcomes of live birth and pregnancy rate for subfertile couples undergoing ART cycles, but further head-to-head comparisons are necessary to identify the superiority of one antioxidant over another.<sup>92</sup>

### Sperm DNA Damage

Successful pregnancies in IVF/ICSI cycles can be obtained using semen samples with a high proportion of DNA damage. Bungum et al. demonstrated that significantly higher clinical pregnancy rates (52.9 versus 22.2 %) and delivery rates (47.1 versus 22.2 %) were obtained after ICSI as compared to IVF when semen samples with high levels of sperm DNA damage were used, as previously suggested.<sup>93</sup>

### Fertilization Defects

Couples should be advised that significantly higher rate of successful pregnancy achieved with IVF-ICSI compared to conventional IVF and IUI in such cases.<sup>62,76,94</sup>

### Donor Insemination

Donor insemination is an alternative when all the above treatment options fail.

### Conclusions

Remarkable developments have been achieved in the field of andrology in the recent years, which significantly improved our understanding of sperm physiology. Novel diagnostic tools envision real time sperm function and may aid in revealing hidden sperm alterations possibly related to infertility. Men facing unexplained infertility are characterised by being childless despite presence of normal semen parameters and normal female partner evaluation. Obviously, classical detailed history taking and physical examination is always necessary to disclose erectile dysfunction problem or irregular coital timing with regard to the peri-ovulatory period. However, when all these measures fail, there is still need to go through more sophisticated and expensive tests to monitor sperm function in more detail. ART may solve the problem of UMF and bypass all the natural barriers that a dysfunctional sperm must face to achieve fertilisation. However, as interventional therapy, ART is not without complications and further studies are needed to refine its role and decrease its impacts on the offspring. ■

- World Health Organization, *WHO Manual for the Standardised Investigation and Diagnosis of the Infertile Couple*, Cambridge: Cambridge University Press, 2000.
- Moghissi KS, Wallach EE, Unexplained infertility, *Fertil Steril*, 1983;39(1):5–21.
- Hamada A, Agarwal A, Unexplained male infertility potential causes and management, *Human Andrology*, 2011;1(1):2–16.
- Esteves SC, Miyaoka R, Agarwal A, An update on the clinical assessment of the infertile male, *Clinics (Sao Paulo)*, 2011;66(4):691–700.
- Sigman M, Lipshultz L, Howard S, Office evaluation of the subfertile male. In: Lipshultz L, Howards S (eds), *Infertility in the Male*, C.S.a.N., Cambridge University Press, 2009;153–76.
- European Association of Urology, Guidelines on Male Infertility 2010. Available at: [www.uroweb.org/gls/pdf/Male%20infertility%202010.pdf](http://www.uroweb.org/gls/pdf/Male%20infertility%202010.pdf) (accessed 27 February 2011).
- Esteves SC, Zini A, Aziz N, et al., Critical Appraisal of World Health Organization's New Reference Values for Human Semen Characteristics and Effect on Diagnosis and Treatment of Subfertile Men, *Urology*, 2012;79(1):16–22.
- Cooper TG, Noonan E, von Eckardstein S, et al., World Health Organization reference values for human semen characteristics, *Hum Reprod Update*, 2010;16(3):231–45.
- World Health Organization, *WHO Laboratory Manual for the Examination of Human Semen and Sperm-cervical Mucus Interaction*, 2nd edition, Cambridge: Cambridge University Press, 1987.
- World Health Organization, *WHO Laboratory Manual for the Examination and Processing of Human Semen*, 5th edition, Geneva: WHO press, 2010.
- World Health Organization, *WHO Laboratory Manual for the Examination of Human Semen and Sperm-cervical Mucus Interaction*, 4th edition, Cambridge, Cambridge University Press, 1999.
- Lipshultz LI, Sigman M, Office evaluation of the subfertile male. In: Howards SS, Lipshultz LI, Niederberger CS (eds), *Infertility in the Male*, Cambridge: Cambridge University Press, 2009;153–76.
- Kopa Z, Berényi M, Inflammatory parameters of the ejaculate. In: GA Björndahl L, Tournaye H, Weidner W (eds), *Clinical Andrology EAU/ESAU Course Guidelines, Informa Healthcare*, 2010;301–8.
- Ayvaliotis B, Rosenfeld D, Cooper G, Conception rates in couples where autoimmunity to sperm is detected, *Fertil Steril*, 1985;43(5):739–42.
- Guzick DS, Overstreet JW, Factor-Litvak P, et al., Sperm morphology, motility, and concentration in fertile and infertile men, *N Engl J Med*, 2001;345(19):1388–93.
- Moghissi KS, Sacco AG, Borin K, Immunologic infertility. I. Cervical mucus antibodies and postcoital test, *Am J Obstet Gynecol*, 1980;136(7):941–50.
- Jones W, The use of antibodies developed by infertile women to identify relevant antigens, *Acta Endocrinol Suppl*

- (Copenh), 1975;194:376–404.
18. Beer AE, Neaves WB, Antigenic status of semen from the viewpoints of the female and male, *Fertil Steril*, 1978;29(1):3–22.
  19. Francavilla F, Santucci R, Barbonetti A, Francavilla S, Naturally-occurring antisperm antibodies in men: interference with fertility and clinical implications. An update, *Front Biosci*, 2007;12:2890–911.
  20. D'Cruz OJ, Haas GG, Lack of complement activation in the seminal plasma of men with antisperm antibodies associated *in vivo* on their sperm, *Am J Reprod Immunol*, 1990;24(2):51–7.
  21. Petersen BH, Lammel CJ, Stites DP, Brooks GF, Human seminal plasma inhibition of complement, *J Lab Clin Med*, 1980;96(4):582–91.
  22. Bronson RA, Antisperm antibodies: a critical evaluation and clinical guidelines, *J Reprod Immunol*, 1999;45(2):159–83.
  23. World Health Organization, *WHO laboratory manual for the examination and processing of human semen*, 5th edition, Geneva: World Health Organization, 2010.
  24. Nicopoulos JD, Gilling-Smith C, Almeida PA, et al., The role of sperm aneuploidy as a predictor of the success of intracytoplasmic sperm injection?, *Hum Reprod*, 2008;23(2):240–50.
  25. Vegetti W, Van Assche E, Frias A, et al., Correlation between semen parameters and sperm aneuploidy rates investigated by fluorescence in-situ hybridization in infertile men, *Hum Reprod*, 2000;15(2):351–65.
  26. Collodel G, Capitani S, Baccetti B, et al., Sperm aneuploidies and low progressive motility, *Hum Reprod*, 2007;22(7):1893–8.
  27. Evenson DP, Darzynkiewicz Z, Melamed MR, Relation of mammalian sperm chromatin heterogeneity to fertility, *Science*, 1980;210(4474):1131–3.
  28. Henkel R, Hajimohammad M, Staf T, et al., Influence of deoxyribonucleic acid damage on fertilization and pregnancy, *Fertil Steril*, 2004;81(4):965–72.
  29. Tesarik J, Greco E, Mendoza C, Late, but not early, paternal effect on human embryo development is related to sperm DNA fragmentation, *Hum Reprod*, 2004;19(3):611–5.
  30. Saleh RA, Agarwal A, Nada EA, et al., Negative effects of increased sperm DNA damage in relation to seminal oxidative stress in men with idiopathic and male factor infertility, *Fertil Steril*, 2003;79(Suppl. 3):1597–605.
  31. Egozcue S, Blanco J, Vendrell JM, et al., Human male infertility: chromosome anomalies, meiotic disorders, abnormal spermatozoa and recurrent abortion, *Hum Reprod Update*, 2000;6(1):93–105.
  32. Rives N, Saint Clair A, Mazurier S, et al., Relationship between clinical phenotype, semen parameters and aneuploidy frequency in sperm nuclei of 50 infertile males, *Hum Genet*, 1999;105(3):266–72.
  33. O'Flynn O'Brien KL, Varghese AC, Agarwal A, The genetic causes of male factor infertility: a review, *Fertil Steril*, 2010;93(1):1–12.
  34. Meistrich ML, Mohapatra B, Shirley R, Zhao M, Roles of transition nuclear proteins in spermiogenesis, *Chromosoma*, 2003;111(8):483–8.
  35. Tatenò H, Kimura Y, Yanagimachi R, Sonication per se is not as deleterious to sperm chromosomes as previously inferred, *Biol Reprod*, 2000;63(1):341–6.
  36. Thomas NS, Hassold TJ, Aberrant recombination and the origin of Klinefelter syndrome, *Hum Reprod Update*, 2003;9(4):309–17.
  37. Celik-Ozenci C, Catalanotti J, Jakab A, et al., Human sperm maintain their shape following decondensation and denaturation for fluorescent in situ hybridization: shape analysis and objective morphometry, *Biol Reprod*, 2003;69(4):1347–55.
  38. Avendaño C, Franchi A, Taylor S, et al., Fragmentation of DNA in morphologically normal human spermatozoa, *Fertil Steril*, 2009;91(4):1077–84.
  39. Yeung C, Sperm Quality and Function Tests. In: Nieschlag E, Behre HM, Nieschlag S, *Andrology, Male Reproductive Health and Dysfunction*, Berlin: Springer-Verlag, 2010;139–54.
  40. Fernández JL, Muriel L, Rivero MT, et al., The sperm chromatin dispersion test: a simple method for the determination of sperm DNA fragmentation, *J Androl*, 2003;24(1):59–66.
  41. Henkel R, Maass G, Hajimohammad M, et al., Urogenital inflammation: changes of leucocytes and ROS, *Andrologia*, 2003;35(5):309–13.
  42. Zini A, Sigman M, Evaluation of Sperm Function. Lipshultz L, Howards SS and Craig S, (eds) *Infertility in the male*, Cambridge: Cambridge University Press 2009. p. 177–98.
  43. Ferlin A, Raicu F, Gatta V, et al., Male infertility: role of genetic background, *Reprod Biomed Online*, 2007;14(6):734–45.
  44. Bungum ML, Giwercman A, Sperm chromatin structure assay (SCSA): a tool in diagnosis and treatment of infertility, *Asian J Androl*, 2010;13(1):69–75.
  45. Agarwal A, Makker K, Sharma R, Clinical relevance of oxidative stress in male factor infertility: an update, *Am J Reprod Immunol*, 2008;59(1):2–11.
  46. The clinical utility of sperm DNA integrity testing, *Fertil Steril*, 2006;86(5 Suppl. 1):S35–7.
  47. Sharma RK, Sabanegh E, Mahfouz R, et al., TUNEL as a test for sperm DNA damage in the evaluation of male infertility, *Urology*, 2010;76(6):1380–6.
  48. Evenson DP, Jost LK, Marshall D, et al., Utility of the sperm chromatin structure assay as a diagnostic and prognostic tool in the human fertility clinic, *Hum Reprod*, 1999;14(4):1039–49.
  49. Garrido N, Martínez-Conejero JA, Jauregui J, et al., Microarray analysis in sperm from fertile and infertile men without basic sperm analysis abnormalities reveals a significantly different transcriptome, *Fertil Steril*, 2009;91(4 Suppl.):1307–10.
  50. Alvarez JG, Storey BT, Spontaneous lipid peroxidation in rabbit and mouse epididymal spermatozoa: dependence of rate on temperature and oxygen concentration, *Biol Reprod*, 1985;32(2):342–51.
  51. Holland MK, Alvarez JG, Storey BT, Production of superoxide and activity of superoxide dismutase in rabbit epididymal spermatozoa, *Biol Reprod*, 1982;27(5):1109–18.
  52. Alvarez JG, Touchstone JC, Blasco L, Storey BT, Spontaneous lipid peroxidation and production of hydrogen peroxide and superoxide in human spermatozoa. Superoxide dismutase as major enzyme protectant against oxygen toxicity, *J Androl*, 1987;8(5):338–48.
  53. Alvarez JG, Storey BT, Lipid peroxidation and the reactions of superoxide and hydrogen peroxide in mouse spermatozoa, *Biol Reprod*, 1984;30(4):833–41.
  54. Aitken RJ, Clarkson JS, Cellular basis of defective sperm function and its association with the genesis of reactive oxygen species by human spermatozoa, *J Reprod Fertil*, 1987;81(2):459–69.
  55. Bennetts RJA, The Sperm Cell Production, Maturation, Fertilization, Regeneration. In: Jonge C, *Reactive oxygen species: friend or foe*, Cambridge: Cambridge University Press, 2006;170–93.
  56. Henkel RR, Leukocytes and oxidative stress: dilemma for sperm function and male fertility, *Asian J Androl*, 2011;13(1):43–52.
  57. Lewis SE, Boyle PM, McKinney KA, et al., Total antioxidant capacity of seminal plasma is different in fertile and infertile men, *Fertil Steril*, 1995;64(4):868–70.
  58. Pasqualotto FF, Sharma RK, Kobayashi H, et al., Oxidative stress in normospermic men undergoing infertility evaluation, *J Androl*, 2001;22(2):316–22.
  59. Fingerova H, Novotny J, Barborik J, et al., Antioxidant capacity of seminal plasma measured by TAS Randox, *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, 2007;151(1):37–40.
  60. Pashayan N, Lyrtzapoulos G, Mathur R, Cost-effectiveness of primary offer of IVF vs. primary offer of IUI followed by IVF (or IUI failures) in couples with unexplained or mild male factor subfertility, *BMC Health Serv Res*, 2006;6:80.
  61. Thaler CD, Cardullo RA, The initial molecular interaction between mouse sperm and the zona pellucida is a complex binding event, *J Biol Chem*, 1996;271(38):23289–97.
  62. Liu DY, Garrett C, Baker HW, Clinical application of sperm-oocyte interaction tests in *in vitro* fertilization--embryo transfer and intracytoplasmic sperm injection programs, *Fertil Steril*, 2004;82(5):1251–63.
  63. Liu de Y, Liu ML, Garrett C, et al., Comparison of the frequency of defective sperm-zona pellucida (ZP) binding and the ZP-induced acrosome reaction between subfertile men with normal and abnormal semen, *Hum Reprod*, 2007;22(7):1878–84.
  64. Liu DY, Clarke GN, Lopata A, et al., A sperm-zona pellucida binding test and *in vitro* fertilization, *Fertil Steril*, 1989;52(2):281–7.
  65. Esteves SC, Sharma RK, Thomas AJ Jr, Agarwal A, Effect of *in vitro* incubation on spontaneous acrosome reaction in fresh and cryopreserved human spermatozoa, *Int J Fertil Womens Med*, 1998;43(5):235–42.
  66. Esteves SC, Sharma RK, Thomas AJ Jr, Agarwal A, Effect of swim-up sperm washing and subsequent capacitation on acrosome status and functional membrane integrity of normal sperm, *Int J Fertil Womens Med*, 2000;45(5):335–41.
  67. Suarez SS, Ho HC, Hyperactivated motility in sperm, *Reprod Domest Anim*, 2003;38(2):119–24.
  68. Garrett C, Liu DY, Clarke GN, et al., Automated semen analysis: 'zona pellucida preferred' sperm morphology and straight-line velocity are related to pregnancy rate in subfertile couples, *Hum Reprod*, 2003;18(8):1643–9.
  69. Mortimer D, Kossakowski J, Mortimer ST, Fussell S, Prediction of fertilizing ability by sperm kinematics. Abstract, OC 05-043, *J Ass Reprod Genet*, 1997;14(5)(Suppl.) 52S.
  70. Lishko PV, Kirichok Y, The role of Hv1 and CatSper channels in sperm activation, *J Physiol*, 2010;588(Pt 23):4667–72.
  71. Suarez SS, Control of hyperactivation in sperm, *Hum Reprod Update*, 2008;14(6):647–57.
  72. Carlson AE, del Camino D, Quill TA, et al., Pharmacological targeting of native CatSper channels reveals a required role in maintenance of sperm hyperactivation, *PLoS One*, 2009;4:16844.
  73. Avenarius MR, Hildebrandt MS, Zhang Y, et al., Human male infertility caused by mutations in the CATSPER1 channel protein, *Am J Hum Genet*, 2009;84(4):505–10.
  74. Liu DY, Baker HW, Inducing the human acrosome reaction with a calcium ionophore A23187 decreases sperm-zona pellucida binding with oocytes that failed to fertilize *in vitro*, *J Reprod Fertil*, 1990;89(1):127–34.
  75. Liu DY, Baker HW, Disordered acrosome reaction of spermatozoa bound to the zona pellucida: a newly discovered sperm defect causing infertility with reduced sperm-zona pellucida penetration and reduced fertilization *in vitro*, *Hum Reprod*, 1994;9(9):1694–700.
  76. Liu DY, Bourne H, Baker HW, High fertilization and pregnancy rates after intracytoplasmic sperm injection in patients with disordered zona pellucida-induced acrosome reaction, *Fertil Steril*, 1997;67(5):955–8.
  77. Esteves SC, Sharma RK, Thomas AJ Jr, Agarwal A, Cryopreservation of human spermatozoa with pentoxifylline improves the post-thaw agonist-induced acrosome reaction rate, *Hum Reprod*, 1998;13(12):3384–9.
  78. Gianaroli L, Magli MC, Ferraretti AP, et al., Birefringence characteristics in sperm heads allow for the selection of reacted spermatozoa for intracytoplasmic sperm injection, *Fertil Steril*, 2010;93(3):807–13.
  79. Esteves SC, Sharma RK, Thomas AJ Jr, Agarwal A, Evaluation of acrosomal status and sperm viability in fresh and cryopreserved specimens by the use of fluorescent peanut agglutinin lectin in conjunction with hypo-osmotic swelling test, *Int Braz J Urol*, 2007;33(3):364–74; discussion 375–6.
  80. Cross NL MP, Hanson FW, Two simple methods for detecting acrosome reacted human sperm, *Gamete Res*, 1986;15(3):213–26.
  81. Miyazaki R, Fukuda M, Takeuchi H, et al., Flow cytometry to evaluate acrosome-reacted sperm, *Arch Androl*, 1990;25(3):243–51.
  82. Aitken RJ, Best FS, Richardson DW, et al., An analysis of sperm function in cases of unexplained infertility: conventional criteria, movement characteristics, and fertilizing capacity, *Fertil Steril*, 1982;38(2):212–21.
  83. Wolf DP, Sokolowski JE, Quigley MM, Correlation of human *in vitro* fertilization with the hamster egg bioassay, *Fertil Steril*, 1983;40(1):53–9.
  84. Chan SY, et al., The relationship between the human sperm hypoosmotic swelling test, routine semen analysis, and the human sperm zona-free hamster ovum penetration assay, *Fertil Steril*, 1985;44(5):668–72.
  85. Chan SY, Fox EJ, Chan MM, et al., Evaluation and treatment of a male factor component to unexplained infertility, *Arch Androl*, 1990;25(3):199–211.
  86. Jarow JP, Diagnostic approach to the infertile male patient, *Endocrinol Metab Clin North Am*, 2007;36(2):297–311.
  87. Brandes M, van der Steen JO, de Bruin JP, et al., Unexplained infertility: overall ongoing pregnancy rate and mode of conception, *Hum Reprod*, 2011;26(2):360–8.
  88. Hull MG, Glazener CM, Kelly NJ, et al., Population study of causes, treatment, and outcome of infertility, *Br Med J (Clin Res Ed)*, 1985;291(6510):1693–7.
  89. Collins JA, Rowe TC, Age of the female partner is a prognostic factor in prolonged unexplained infertility: a multicenter study, *Fertil Steril*, 1989;52(1):15–20.
  90. Nagy ZP, Liu J, Joris H, et al., Results of 55 intracytoplasmic sperm injection cycles in the treatment of male-immunological infertility, *Hum Reprod*, 1995;10(7):1777–80.
  91. Esteves SC, Schneider DT, Verza Jr S, Influence of antisperm antibodies in the semen on intracytoplasmic sperm injection outcome, *Int Braz J Urol*, 2007;33(6):795–802.
  92. Showell MG, Brown J, Yazdani A, et al., Antioxidants for male subfertility, *Cochrane Database Syst Rev*, 2012(1):CD007411.
  93. Larson-Cook KL, Brannian JD, Hansen KA, et al., Relationship between the outcomes of assisted reproductive techniques and sperm DNA fragmentation as measured by the sperm chromatin structure assay, *Fertil Steril*, 2003;80(4):895–902.
  94. Liu DY, Baker HW, Evaluation and assessment of semen for IVF/ICSI, *Asian J Androl*, 2002;4(4):281–5.

Unexplained infertility is a diagnosis reserved for couples in whom routine semen analysis is within normal values and female infertility factors have been ruled out. Its reported prevalence ranges from 6%–27 % depending on how exhaustive the patient work-up is. Despite differing according to urological societies, recommendation for male infertility evaluation usually takes routine semen analysis results as surrogates for fertility potential. Male infertility evaluation, however, must go far beyond counting spermatozoa and assessing motility and morphology. They are still lacking, not only because the reasons for infertility remain. Unexplained Male Infertility – Looking Beyond Routine Semen Analysis. *European Urological Review* 93. Infertility. Hamada, A., Esteves, S.C. and Agarwal, A. (2012) Unexplained Male Infertility – Looking beyond Routine Semen Analysis. *European Urological Review*, 7, 90-96. has been cited by the following article – KEYWORDS: Antisperm Antibody, Immune Infertility, Unexplained Infertility, Democratic Republic of Congo. JOURNAL NAME: *Open Journal of Obstetrics and Gynecology*, Vol.9 No.5, May 24, 2019. ABSTRACT: Introduction: Infertility in a couple is a stressful situation. Semen Abnormality Patterns and Parameters in Male Partners of Infertile Couples in Dakar (Senegal). Mama Sy Diallo, Abdoulaye Sagna Diallo, Pyrrhus Fotso, Babacar Diao, Yoro Diallo, Oumar Faye. DOI: 10.4236/oju.2015.59024 4 957 Downloads 5 613 Views Citations. Unexplained male infertility (UMI) is a diagnosis reserved for men in whom routine semen analysis results are within normal values, and physical as well as endocrine abnormalities were ruled out. Currently, routine semen analysis remains the backbone of the evaluation of the UMI [3]. Technological developments in the field of metabolomics may bring robust and cost-effective clinical tools to fix the shortcomings of the routine semen analysis and provide new insights into UMI. Seminal plasma has long been used as a key source to investigate male infertility. It has been reported that infertile Unexplained male infertility is a diagnosis reserved for men in whom routine semen analyses results are within normal values and physical as well as endocrine abnormalities were ruled out. In addition to erectile problems and coital factors, immunologic causes and sperm dysfunction may contribute to such condition. New etiologies of unexplained male infertility include low level leukocytospermia and mitochondrial DNA polymerase gene polymorphism. Contemporary andrology may reveal cellular and sub-cellular sperm dysfunctions which may explain subfertility in such cases, thus aiding the clinic